ClinicalTrials.gg
RecruitingNCT07378956SAFE-DMUpdated Apr 13, 2026

Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus

An interventional study of VUNO Med®-Fundus AI™ in Diabetic Retinopathy (DR), Diabete Mellitus and Fundus Photography, sponsored by VUNO Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by VUNO Inc. · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of — 2 open to participants now, 4 under way, none of them phase 3. Diabetic Retinopathy · Korea, Republic of.

Planned enrollment
2nd of 11
340 · median 49
Started
2026
with 1 other
No phase
3 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 14th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.

Read the detailed description

The primary objective of this study is to compare the true referral rate between patients with VUNO Med®-Fundus AI™-assisted screening (intervention group) and those receiving usual clinical care without AI assistance (control group) among patients with diabetes mellitus.

03

Conditions studied

  • Diabetic Retinopathy (DR)
  • Diabete Mellitus
  • Fundus Photography
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 years or older.
  • A documented diagnosis of type 2 diabetes mellitus.
  • Ability to communicate adequately and provide written for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • A prior diagnosis of diabetic retinopathy at the time of screening.
  • A history of ophthalmic surgery within 6 months prior to the screening date.
  • A diagnosis of type 1 diabetes mellitus.
  • Pregnancy at the time of screening.
  • Any condition that, in the opinion of the investigator, would make participation in the study infeasible or inappropriate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    Intervention group

    For participants assigned to the intervention group, VUNO Med®-Fundus AI™ will be applied to the acquired fundus images, and the AI-generated outputs will be shown to clinicians during routine care.

    Device: VUNO Med®-Fundus AI™

  • No intervention
    Control group

    For participants assigned to the control group, fundus images will be interpreted according to usual clinical care without AI assistance.

Interventions

  • DeviceVUNO Med®-Fundus AI™

    VUNO Med®-Fundus AI™ is an artificial intelligence-based fundus image detection and diagnostic support software. The software automatically identifies abnormal retinal findings and provides information on the type and location of detected abnormalities to aid clinical decision-making.

06

What researchers measure

Primary outcomes

  1. True Referral Rate

    The true referral rate is defined as the proportion of subjects who were diagnosed with diabetic retinopathy by an ophthalmologist among those referred to ophthalmology with suspected diabetic retinopathy. The true referral rate will be compared between the intervention and control groups.

    Time frame: within 6 months

Secondary outcomes

  1. Diabetic Retinopathy (DR) Diagnosis Rate

    Proportion of subjects diagnosed with diabetic retinopathy among all enrolled subjects will be compared between the intervention group and the control group.

    Time frame: Within 6 months

  2. Odds Ratio

    Odds ratio between the diagnosis of diabetic retinopathy and the application of the AI system among subjects referred to ophthalmology will be calculated.

    Time frame: Within 6 months

  3. Referral Rate

    Proportion of subjects referred to ophthalmology for suspected diabetic retinopathy among all enrolled subjects will be compared between the intervention group and the control group.

    Time frame: Within 6 months

  4. Time to Diabetic Retinopathy Diagnosis

    Time interval from the diagnosis of diabetes mellitus to confirmed diagnosis of diabetic retinopathy based on ophthalmologic evaluation among referred subjects will be compared between the intervention group and the control group.

    Time frame: Within 6 months

  5. Performance of the AI System in Detecting Diabetic Retinopathy

    Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of the AI system will be calculated in comparison with ophthalmologist-confirmed diagnoses.

    Time frame: Within 6 months

  6. Accuracy of Referral for Diabetic Retinopathy

    Proportion of subjects whose referral decisions (referral or non-referral) are concordant with ophthalmologist-confirmed DR status will be compared between the intervention group and the control group.

    Time frame: Within 6 months

  7. Adherence Rate

    Proportion of referred subjects who attend an ophthalmology department will be compared between the intervention group and the control group.

    Time frame: Within 6 months

Other outcomes

  1. Interim Analysis

    One interim analysis will be conducted when 50% of subjects have completed all study visits. The purpose of this analysis is to review the status of subject dropouts and the reasons for dropout in each group. This procedure will be conducted by a statistician who is independent of the study conduct.

    Time frame: Within 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The institutional dataset used in this study, along with de-identified results, is available upon reasonable request for purposes such as systematic review or meta-analysis, only with approval from the corresponding author and the official approval of local IRB.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.

Of 126 interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Apr 7, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07378956
Lead sponsor
VUNO Inc.
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Apr 7, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Hee Jun Park
Contact
heejun.park@vuno.co
82-10-7101-2844

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion